Literature DB >> 32162165

Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease.

Paolo Ruggeri1, Lucia Lo Monaco2, Olimpia Musumeci3, Graziana Tavilla3, Michele Gaeta4, Gaetano Caramori2, Antonio Toscano3.   

Abstract

INTRODUCTION: Late-Onset Pompe Disease (LOPD) is characterized by progressive limb-girdle muscle weakness and respiratory dysfunction. Diaphragm is the most impaired muscle in LOPD and its dysfunction cause major respiratory symptoms. The aim of this study was to evaluate the correlation between diaphragm thickness and mobility assessed by ultrasonography and respiratory function and muscle strength tests in patients with LOPD.
METHODS: 17 patients with LOPD (9 female, 47 ± 15 years) and 17 age and gender-matched healthy controls underwent spirometry, muscle strength testing, and ultrasound evaluation of diaphragm excursion and thickness.
RESULTS: The following parameters were significantly reduced in LOPD patients versus controls (all p < 0.001): forced vital capacity (FVC) in seated and supine position, maximum inspiratory and expiratory pressure (MIP and MEP), diaphragm excursion, thickness at functional residual capacity (FRC) and total lung capacity (TLC), and thickness fraction (TF). Ultrasound studies of diaphragm thickness at FRC correlated with MIP (r = 0.74; p < 0.0001) and seated FVC(r = 0.73; p < 0.05). Diaphragm thickness at TLC correlated with MIP (r = 0.85; p < 0.0001) and FVC in both seated (r = 0.77; p < 0.0001) and supine position (r = 0.68; p < 0.05). TF correlated significantly with MIP (r = 0.80; p < 0.001), FVC in both seated (r = 0.66; p < 0,005) and supine position (r = 0.61; p < 0.05). Interestingly diaphragm thickness at FRC correlated with disease duration (years) in LOPD patients (r = -0.53; p < 0,05). Ultrasound diaphragm mobility correlated with diaphragm thickness at TLC(r = 0.87; p < 0.0001), FRC (r = 0.84; p < 0.005) and TF (r = 0.73; p < 0.05). Moreover diaphragm mobility correlated with FVC in seated(r = 0.79; p < 0.005) and supine position(r = 0.74; p < 0.05) and MIP (r = 0.81; p < 0.005).
CONCLUSION: Diaphragm ultrasonography is a simple and reproducible technique for manage respiratory dysfunction in LOPD patients.

Entities:  

Keywords:  Diaphragm; Late-onset Pompe disease; Lung function; Respiratory muscle strength; Ultrasonography

Mesh:

Year:  2020        PMID: 32162165     DOI: 10.1007/s10072-020-04316-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  4 in total

Review 1.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

2.  Correlation Between Respiratory Accessory Muscles and Diaphragm Pillars MRI and Pulmonary Function Test in Late-Onset Pompe Disease Patients.

Authors:  David Reyes-Leiva; Jorge Alonso-Pérez; Mercedes Mayos; Claudia Nuñez-Peralta; Jaume Llauger; Izaskun Belmonte; Irene Pedrosa-Hernández; Sonia Segovia; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-03-01       Impact factor: 4.003

3.  Chest MRI to diagnose early diaphragmatic weakness in Pompe disease.

Authors:  Laurike Harlaar; Pierluigi Ciet; Gijs van Tulder; Alice Pittaro; Harmke A van Kooten; Nadine A M E van der Beek; Esther Brusse; Piotr A Wielopolski; Marleen de Bruijne; Ans T van der Ploeg; Harm A W M Tiddens; Pieter A van Doorn
Journal:  Orphanet J Rare Dis       Date:  2021-01-07       Impact factor: 4.123

4.  Association of diaphragm thickness and echogenicity with age, sex, and body mass index in healthy subjects.

Authors:  Jeroen L M van Doorn; Juerd Wijntjes; Christiaan G J Saris; Coen A C Ottenheijm; Nens van Alfen; Jonne Doorduin
Journal:  Muscle Nerve       Date:  2022-06-09       Impact factor: 3.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.